This is a preview of subscription content, log in via an institution to check access.
Notes
This profile has been selected from R&D Insight™, a pharmaceutical intelligence database produced by Adis International Ltd.
References
Neurocrine Biosciences, Inc. Neurocrine Biosciences, Inc. reports positive phase II results with new insomnia drug. Media Release: [3 pages], 30 Nov 1999. Available from URL: http://www.neurocrine.com
Neurocrine Biosciences Inc. Neurocrine Biosciences announces positive results from phase I and II clinical trials with NBI-34060. Media Release: [3 pages], 8 Jan 2001. Available from URL: http://www.neurocrine.com
Neurocrine Biosciences Inc. Neurocrine Biosciences announces positive phase II results with NBI-34060 in patients with chronic insomnia. Media Release: [2 pages], 17 Jul 2001. Available from URL: http://www.neurocrine.com
Neurocrine Biosciences Inc. Neurocrine Biosciences announces positive phase II efficacy results with NBI-34060 immediate release in elderly patients with primary (chronic) insomnia. Media Release: [4 pages], 14 Dec 2001. Available from URL: http://www.neurocrine.com
Neurocrine Biosciences Inc. Neurocrine Biosciences announces positive phase II efficacy and safety results with NBI-34060 modified release (MR). Media Release: [2 pages], 18 Jan 2002. Available from URL: http://www.neurocrine.co
Rights and permissions
About this article
Cite this article
Indiplon. Drugs R&D 3, 197–199 (2002). https://doi.org/10.2165/00126839-200203030-00012
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200203030-00012